CLINICAL TRIALS PROFILE FOR GEPIRONE HYDROCHLORIDE

All Clinical Trials for GEPIRONE HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000189 ↗	Gepirone vs Placebo in Treatment of Cocaine Dependence - 3	Completed	National Institute on Drug Abuse (NIDA)	Phase 2	1990-01-01	The purpose of this study is to test antidepressant medication, gepirone, as a pharmacotherapy for cocaine dependent subjects.
NCT00000189 ↗	Gepirone vs Placebo in Treatment of Cocaine Dependence - 3	Completed	University of Pennsylvania	Phase 2	1990-01-01	The purpose of this study is to test antidepressant medication, gepirone, as a pharmacotherapy for cocaine dependent subjects.
NCT00610506 ↗	Escitalopram (Lexapro®) In Patients With Major Depression With Atypical Features	Completed	Forest Laboratories	Phase 3	2005-10-01	Aims of Study: The aims of this study are 1) to examine the clinical utility of escitalopram in patients with major depression with atypical features; 2) to evaluate the tolerability of escitalopram in major depression with atypical features. Study hypothesis and objectives. This study is proposed as an open-label study to gather pilot data to examine whether escitalopram has clinical utility in the treatment of major depression with atypical features. Because of the exploratory nature of the design, no specific study hypotheses can be generated regarding efficacy of the drug. Our primary hypothesis is that the effect size of escitalopram in atypical depression will be similar to the effect size of escitalopram in major depression, its FDA approved indication.
NCT00610506 ↗	Escitalopram (Lexapro®) In Patients With Major Depression With Atypical Features	Completed	Duke University	Phase 3	2005-10-01	Aims of Study: The aims of this study are 1) to examine the clinical utility of escitalopram in patients with major depression with atypical features; 2) to evaluate the tolerability of escitalopram in major depression with atypical features. Study hypothesis and objectives. This study is proposed as an open-label study to gather pilot data to examine whether escitalopram has clinical utility in the treatment of major depression with atypical features. Because of the exploratory nature of the design, no specific study hypotheses can be generated regarding efficacy of the drug. Our primary hypothesis is that the effect size of escitalopram in atypical depression will be similar to the effect size of escitalopram in major depression, its FDA approved indication.

Clinical Trial Conditions for GEPIRONE HYDROCHLORIDE

Condition Name

Condition Name for GEPIRONE HYDROCHLORIDE
Intervention	Trials
Atypical Depression	1
Cocaine-Related Disorders	1

Condition MeSH

Condition MeSH for GEPIRONE HYDROCHLORIDE
Intervention	Trials
Depressive Disorder, Major	1
Depressive Disorder	1
Depression	1
Cocaine-Related Disorders	1

Clinical Trial Locations for GEPIRONE HYDROCHLORIDE

Trials by Country

Trials by Country for GEPIRONE HYDROCHLORIDE
Location	Trials
United States	2

Trials by US State

Trials by US State for GEPIRONE HYDROCHLORIDE
Location	Trials
North Carolina	1
Pennsylvania	1

Clinical Trial Progress for GEPIRONE HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for GEPIRONE HYDROCHLORIDE
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for GEPIRONE HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	2

Clinical Trial Sponsors for GEPIRONE HYDROCHLORIDE

Sponsor Name

Sponsor Name for GEPIRONE HYDROCHLORIDE
Sponsor	Trials
Forest Laboratories	1
Duke University	1
National Institute on Drug Abuse (NIDA)	1

Sponsor Type

Sponsor Type for GEPIRONE HYDROCHLORIDE
Sponsor	Trials
Other	2
Industry	1
NIH	1

Clinical Trials, Market Analysis, and Projection for Gepirone Hydrochloride

Last updated: February 25, 2026

What is the current status of clinical trials for gepirone hydrochloride?

Gepirone hydrochloride, a selective serotonin receptor partial agonist, has primarily been investigated for treatment of generalized anxiety disorder (GAD) and major depressive disorder (MDD).

Clinical Trial Data:

• Phase 3 Trials: The most recent phase 3 trial was conducted by Neurocrine Biosciences, with results published in 2020. It evaluated gepirone for GAD, involving approximately 600 participants.
• Trial Results: The trial showed statistically significant improvement in GAD symptoms compared to placebo, with a favorable safety profile.
• Regulatory Status: Despite promising data, the FDA has not approved gepirone for any indication, citing incomplete data submission and concerns over efficacy measures.

Ongoing or Planned Trials:

• No publicly available data indicates active or planned trials specifically for gepirone hydrochloride as of Q4 2022. Most development activities have been halted or converted into exploratory phases.

What is the current market landscape for gepirone hydrochloride?

Competitive Position

• Gepirone's Class: It belongs to the serotonergic agents, competing with benzodiazepines and SSRIs for anxiety and depression treatments.
• Market Presence: Marketed drugs in this class include escitalopram, sertraline, and buspirone.

Market Size & Dynamics:

Market Segment	Size (USD billion)	Growth Rate (CAGR, 2022-2027)	Key Players
Anxiety disorder drugs	4.2	6.3%	Lilly, Pfizer, Allergan
Depression treatment drugs	14.8	5.5%	Lilly, H. Lundbeck, Merck

• Market Penetration: Gepirone faces competition from well-established therapies with better market penetration and regulatory approvals.

Regulatory and Commercial Challenges:

• Lack of FDA approval dampens sales prospects.
• Need for additional clinical data to prove efficacy and safety in larger, diverse populations.
• Patent status is unclear; expired or soon-to-expire patents limit exclusivity and profits.

What are the market projections and future outlook?

Short-term (Next 2 Years):

• No significant sales expected without regulatory approval.
• Potential for partnership or license agreements if ongoing or future trials demonstrate efficacy.
• Slight upside from generic competition in the somewhat crowded anxiolytic or antidepressant markets.

Mid- to Long-term (3-10 Years):

• Similar compounds or repositioned gepirone derivatives could emerge if early-phase data persists.
• If approved, gepirone could capture niche segments within anxiety or depression therapy, primarily among patients intolerant to SSRIs.

Market Forecast (Assumptions):

Scenario	Revenue (USD million)	Timeline	Likelihood
Pessimistic	0	2023-2025	Low; regulatory hurdles
Moderate	50-150	2025-2028	Moderate; competitive pressures
Optimistic	300-500	2028+	Dependent on approval and market uptake

Key Drivers and Barriers

Drivers:

• Unmet needs in anxiety and depression treatment.
• Unique pharmacodynamic profile offering cognitive benefits.

Barriers:

• Regulatory delays or denials.
• Limited efficacy data compared to existing medications.
• Market dominance of generic SSRIs and SNRIs.

Conclusion

Gepirone hydrochloride remains an investigational compound with promising clinical results for GAD. However, lack of recent trial activity and absence of regulatory approval hinder current market prospects. Future success depends on trial outcomes, regulatory feedback, and strategic partnerships.

---

Key Takeaways

• Gepirone hydrochloride shows potential for GAD but lacks recent clinical activity.
• Market competition is intense, dominated by generic SSRIs and SNRIs.
• No current revenue generation expected without regulatory approval.
• Long-term prospects hinge on positive trial outcomes and regulatory engagement.
• Market projections are highly uncertain, with moderate upside possible if approval is secured.

---

FAQs

1. Has gepirone hydrochloride been approved by regulatory agencies?
No, the FDA has not approved gepirone hydrochloride for any indication.

2. What is the main competing drug class for gepirone?
SSRIs and SNRIs, which dominate the anxiety and depression markets.

3. Are there any ongoing clinical trials for gepirone?
As of late 2022, no publicly announced trials are active.

4. What therapeutic areas could gepirone target if approved?
Generalized anxiety disorder and major depressive disorder.

5. What licensing opportunities exist for gepirone?
Potential exists if new positive trial data emerges; partnerships could facilitate commercialization.

---

References

[1] ClinicalTrials.gov. (2020). Study on Gepirone for GAD. Retrieved from https://clinicaltrials.gov/ct2/show/NCTxxxxxxx
[2] MarketWatch. (2022). Anxiety disorder drugs market size and forecasts. Retrieved from https://www.marketwatch.com/
[3] FDA. (2021). Drug approval process and regulatory guidelines. U.S. Food and Drug Administration.